Skip to content
View Report
2020 REPORT AND RESOURCES
That’s why with our 2020 Janssen U.S. Transparency Report, we outline our vision of better health for all and continue the journey we began with the first report.

Learn more by downloading our 2020 Janssen U.S. Transparency Report and the Executive Summary.
5 Fast Facts
Supporting Access to Our Innovators  Fast Fact
Our Rebates, Discounts and Fees in 2020
$29.4 billion—Rebates, discounts and fees provided in 2020 to payers and others in the health system— more than half the list price (53%) of our medicines.
Fast Fact - Driving Treatment for Advance Patients Fact
Driving Treatment Advances for Patients
Between 2016-2020 we invested $42.2 billion in R&D.
Fact Fact - Our R&D Investment Exceeds Our Spending on Sales and Marketing
Our R&D Investment Exceeds Our Spending on Marketing and Sales
Our R&D investment has increased an average of 8.1% for the past five years.
Fast Facts - Our Discounts have Grown from 2016-2020
Our Discounts Have Grown From 2016-2020
Since 2016, the rebates and discounts we provide have nearly tripled, reflecting payers’ growing negotiating power.
Discounts to Government Programs Support Patient Access
Discounts to Government Programs Support Patient Access
We provide U.S. government programs with substantial discounts.
“We want disclosures like these to shape the conversation about how to sustain the innovation that’s the hallmark of the U.S. health system. That’s the legacy we’ve established with the Janssen U.S. Transparency Report and the legacy we are humbled to carry forward.”
Scott White, Company Group Chairman North America Pharmaceuticals, Johnson & Johnson
Scott White
Company Group Chairman North America Pharmaceuticals
Johnson & Johnson

Internet Explorer is not supported by this website.

For optimal browsing we recommend using Chrome, Safari, or Firefox.